Last reviewed · How we verify
TPN-672
At a glance
| Generic name | TPN-672 |
|---|---|
| Also known as | single dose of TPN-672 maleate tablet, TPN-672 maleate tablet |
| Sponsor | Jiangsu Kanion Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TPN672 Tablets Maleate in Patients With Schizophrenia (PHASE1)
- Tolerance, PK and PD Effects Study of TPN-672 in Chinese Healthy Volunteers (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TPN-672 CI brief — competitive landscape report
- TPN-672 updates RSS · CI watch RSS
- Jiangsu Kanion Pharmaceutical Co., Ltd portfolio CI